Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 20, 2019
Early <sup>18</sup>F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with NivolumabAiping Chen, Fatima-Zohra Mokrane, Lawrence H Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2022
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS StudyCaroline Houillier, Sylvain Dureau, Luc Taillandier, et al.
Nature Communications|February 22, 2018
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemiaCarmen D Herling, Nima Abedpour, Jonathan Weiss, et al.
Nature Communications|August 4, 2019
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancerMarcel A Dammert, Johannes Brägelmann, Rachelle R Olsen, et al.
Cell|January 8, 2019
UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive TumorsRon D Jachimowicz, Filippo Beleggia, Jörg Isensee, et al.
Leukemia|November 7, 2019
ATM activity in T cells is critical for immune surveillance of lymphoma in vivoArina Riabinska, Daria Lehrmann, Ron Daniel Jachimowicz, et al.
Nature Communications|December 18, 2025
Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progressionAriadne Androulidaki, Fanyu Liu, Christina M Bebber, et al.
Haematologica|September 2, 2018
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphomaRémy Gressin, Nicolas Daguindau, Adrian Tempescul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I TrialXavier Leleu, Guillemette Fouquet, Valentine Richez, et al.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Pageof 6